A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions

Healthy Volunteers

Interventions

DRUG

SHP681

Participants will receive SC injection of SHP681 in the abdomen.

OTHER

Placebo

Participants will receive SC injection of placebo matched to SHP681 in the abdomen.

Trial Locations (1)

New Orleans Center for Clinical Research, Knoxville